A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease
Purpose Preclinical evidence indicates that the bone marrow microenvironment provides a
protective niche for leukemic stem cells, allowing them to evade the effects of BCR-ABL
tyrosine kinase inhibitors (TKIs), but that targeting of the JAK-STAT pathway with the JAK2
inhibitor ruxolitinib increases TKI-induced apoptosis. A phase I clinical trial (NCT01702064)
investigated the tolerability and safety of treating chronic-phase chronic myeloid leukemia
patients with ruxolitinib in combination with the BCR-ABL TKI nilotinib and explored initial …
protective niche for leukemic stem cells, allowing them to evade the effects of BCR-ABL
tyrosine kinase inhibitors (TKIs), but that targeting of the JAK-STAT pathway with the JAK2
inhibitor ruxolitinib increases TKI-induced apoptosis. A phase I clinical trial (NCT01702064)
investigated the tolerability and safety of treating chronic-phase chronic myeloid leukemia
patients with ruxolitinib in combination with the BCR-ABL TKI nilotinib and explored initial …
以上显示的是最相近的搜索结果。 查看全部搜索结果